Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

37 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Vitamin D deficiency in a European inflammatory bowel disease inception cohort: an Epi-IBD study.
Chetcuti Zammit S, Ellul P, Girardin G, Valpiani D, Nielsen KR, Olsen J, Goldis A, Lazar D, Shonová O, Nováková M, Sebastian S, Whitehead E, Carmona A, Martinez-Cadilla J, Dahlerup JF, Kievit ALH, Thorsgaard N, Katsanos KH, Christodoulou DK, Magro F, Salupere R, Pedersen N, Kjeldsen J, Carlsen K, Ioannis K, Bergemalm D, Halfvarson J, Duricova D, Bortlik M, Collin P, Oksanen P, Kiudelis G, Kupcinskas L, Kudsk K, Andersen V, O'Morain C, Bailey Y, Doron S, Shmuel O, Almer S, Arebi N, Misra R, Čuković-Čavka S, Brinar M, Munkholm P, Vegh Z, Burisch J. Chetcuti Zammit S, et al. Among authors: bergemalm d. Eur J Gastroenterol Hepatol. 2018 Nov;30(11):1297-1303. doi: 10.1097/MEG.0000000000001238. Eur J Gastroenterol Hepatol. 2018. PMID: 30134383
Long-term effectiveness of vedolizumab in inflammatory bowel disease: a national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG).
Eriksson C, Marsal J, Bergemalm D, Vigren L, Björk J, Eberhardson M, Karling P, Söderman C; SWIBREG Vedolizumab Study Group; Myrelid P, Cao Y, Sjöberg D, Thörn M, Karlén P, Hertervig E, Strid H, Ludvigsson JF, Almer S, Halfvarson J. Eriksson C, et al. Among authors: bergemalm d. Scand J Gastroenterol. 2017 Jun-Jul;52(6-7):722-729. doi: 10.1080/00365521.2017.1304987. Epub 2017 Mar 31. Scand J Gastroenterol. 2017. PMID: 28362144
The use of 5-aminosalicylate for patients with Crohn's disease in a prospective European inception cohort with 5 years follow-up - an Epi-IBD study.
Burisch J, Bergemalm D, Halfvarson J, Domislovic V, Krznaric Z, Goldis A, Dahlerup JF, Oksanen P, Collin P, de Castro L, Hernandez V, Turcan S, Belousova E, D'Incà R, Sartini A, Valpiani D, Giannotta M, Misra R, Arebi N, Duricova D, Bortlik M, Gatt K, Ellul P, Pedersen N, Kjeldsen J, Andersen KW, Andersen V, Katsanos KH, Christodoulou DK, Sebastian S, Barros L, Magro F, Midjord JM, Nielsen KR, Salupere R, Kievit HA, Kiudelis G, Kupčinskas J, Fumery M, Gower-Rousseau C, Kaimakliotis IP, Schwartz D, Odes S, Lakatos L, Lakatos PL, Langholz E, Munkholm P; Epi-IBD group. Burisch J, et al. Among authors: bergemalm d, d inca r. United European Gastroenterol J. 2020 Oct;8(8):949-960. doi: 10.1177/2050640620945949. Epub 2020 Jul 26. United European Gastroenterol J. 2020. PMID: 32715989 Free PMC article.
Faecal microbiota signatures of IBD and their relation to diagnosis, disease phenotype, inflammation, treatment escalation and anti-TNF response in a European Multicentre Study (IBD-Character).
Vatn S, Carstens A, Kristoffersen AB, Bergemalm D, Casén C, Moen AEF, Tannaes TM, Lindstrøm J, Detlie TE, Olbjørn C, Lindquist CM, Söderholm JD, Gomollón F, Kalla R, Satsangi J, Vatn MH, Jahnsen J, Halfvarson J, Ricanek P; IBD-Character Consortium. Vatn S, et al. Among authors: bergemalm d. Scand J Gastroenterol. 2020 Oct;55(10):1146-1156. doi: 10.1080/00365521.2020.1803396. Epub 2020 Aug 11. Scand J Gastroenterol. 2020. PMID: 32780604
Serum proteomic profiling at diagnosis predicts clinical course, and need for intensification of treatment in inflammatory bowel disease.
Kalla R, Adams AT, Bergemalm D, Vatn S, Kennedy NA, Ricanek P, Lindstrom J, Ocklind A, Hjelm F, Ventham NT, Ho GT, Petren C, Repsilber D, Söderholm J, Pierik M, D'Amato M, Gomollón F, Olbjorn C, Jahnsen J, Vatn MH, Halfvarson J, Satsangi J. Kalla R, et al. Among authors: bergemalm d, d amato m. J Crohns Colitis. 2021 May 4;15(5):699-708. doi: 10.1093/ecco-jcc/jjaa230. J Crohns Colitis. 2021. PMID: 33201212 Free PMC article.
Real-world effectiveness of vedolizumab in inflammatory bowel disease: week 52 results from the Swedish prospective multicentre SVEAH study.
Eriksson C, Rundquist S, Lykiardopoulos V, Udumyan R, Karlén P, Grip O, Söderman C, Almer S, Hertervig E, Marsal J, Gunnarsson J, Malmgren C, Delin J, Strid H, Sjöberg M, Öberg D, Bergemalm D, Hjortswang H, Halfvarson J; SWIBREG SVEAH Study Group. Eriksson C, et al. Among authors: bergemalm d. Therap Adv Gastroenterol. 2021 Jul 3;14:17562848211023386. doi: 10.1177/17562848211023386. eCollection 2021. Therap Adv Gastroenterol. 2021. PMID: 34276808 Free PMC article.
Clinical effectiveness of golimumab in ulcerative colitis: a prospective multicentre study based on the Swedish IBD Quality Register, SWIBREG.
Eriksson C, Visuri I, Vigren L, Nilsson L, Kärnell A, Hjortswang H, Bergemalm D; GO SWIBREG study group; Almer S, Hertervig E, Karlén P, Strid H, Halfvarson J. Eriksson C, et al. Among authors: bergemalm d. Scand J Gastroenterol. 2021 Nov;56(11):1304-1311. doi: 10.1080/00365521.2021.1963466. Epub 2021 Aug 20. Scand J Gastroenterol. 2021. PMID: 34415803 Free article.
37 results